ctDNA in CRC Management: Evolving Approaches for Personalized Care
Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.
Video Player is loading.
EP: 1.Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
Now Viewing
EP: 2.ctDNA in CRC Management: Evolving Approaches for Personalized Care
EP: 3.MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring
EP: 4.MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control
EP: 5.DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
EP: 6.ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies
EP: 7.GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
EP: 8.GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC
EP: 9.Treatment Strategies in ctDNA-Positive CRC
EP: 10.GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC
EP: 11.CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis
Recent Videos
MonumenTAL-1: Implications of Talquetamab, Prior TCR, and Sequencing for R/R MM
Insights From MonumenTAL-1: Impressions of Updated Efficacy Outcomes
CEPHEUS Trial: Design/Baseline Characteristics
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
Later R/R MM Treatment Landscape and Unmet Needs
COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
Related Content
